Wan-Ling Hsu,¹ Dale L. Preston,^2,* Midori Soda,¹ Hiromi Sugiyama,¹ Sachiyo Funamoto,¹ Kazunori Kodama,¹ Akiro Kimura,³ Nanao Kamada,⁴ Hiroo Dohy,⁵ Masao Tomonaga,⁶ Masako Iwanaga,⁷ Yasushi Miyazaki,⁸ Harry M. Cullings,¹ Akihiko Suyama,¹ Kotaro Ozasa,¹ Roy E. Shore,¹ Kiyohiko Mabuchi<sup>9

1</sup>aRadiation Effects Research Foundation, Hiroshima and Nagasaki, Japan;
²bHirosoft International, Eureka, California;
³cDepartment of Hematology and Oncology, Hiroshima University, Hiroshima, Japan;
⁴dHiroshima A-bomb Survivors Relief Foundation, Hiroshima, Japan;
⁵eHiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan;
⁶fThe Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;
⁷gGraduate School of Public Health, Teikyo University, Tokyo, Japan;
⁸hDepartment of Hematology, Nagasaki University, Nagasaki, Japan; and
⁹iDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

^*Address for correspondence: Department of Statistics, Radiation Effects Research Foundation, 5-2 Hijiyama Koen, Minami-Ku, Hiroshima 732-0815, Japan; e-mail: preston@hirosoft.net.